Ranibizumab for the treatment of degenerative ocular conditions

Magdalini Triantafylla¹
Horace F Massa²
Doukas Dardabounis¹
Zisis Gatziofas¹
Vassilios Kozobolis¹
Konstantinos Ioannakis¹
Irфан Perente¹,²
Georgios D Panos¹,²

¹Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece; ²Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Switzerland; ³Beyoğlu Eye Research and Teaching Hospital, Istanbul University, Istanbul, Turkey

Abstract: Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these conditions. Ranibizumab, a humanized monoclonal antibody antigen-binding fragment, which inhibits all biologically active isofoms of VEGF-A, is still the gold standard treatment for the majority of these pathological entities. In this review, we present the results of the most important clinical trials concerning the efficacy and safety of ranibizumab for the treatment of degenerative ocular conditions.

Keywords: age-related macular degeneration, diabetic macular edema, retinal vein occlusion, anti-VEGF, safety, efficacy, quality of life

Introduction to degenerative ocular conditions and their management

Age-related macular degeneration

The disease was first described by Holloway and Verhoeff in 1929 and has grown to be an important public health problem ever since, with various resources trying to demonstrate the mechanisms being evolved.¹⁻³ As the population ages, the percentage of patients suffering from age-related macular degeneration (AMD) increases rapidly, new therapeutic options are constantly under development, and research focuses on understanding the mechanisms related to the disease and the role of human genetics and environmental risk factors.⁴

AMD is a multifactorial disease characterized by progressive degeneration of photoreceptors and the retinal pigment epithelium (RPE) in the macular region of the retina, resulting in irreversible central vision loss. It is the leading cause of irreversible vision loss in individuals over 65 years in developed countries.⁵ In the US alone, over 10 million individuals have AMD, regardless of type. These numbers are projected to increase by 50% over the next 10 years.⁶

AMD is classified into two types: non-neovascular (dry AMD) and neovascular (wet AMD), with the neovascular form of AMD responsible for the most severe and rapid visual loss, although it is less common, affecting only 10% of AMD patients; it is characterized by choroidal neovascularization (CNV) development. CNV consists of immature new pathological blood vessels growing from the choroid towards the retina, which can leak or exude fluid, causing damage to the retinal layers by separating its structures and resulting in loss of vision. Finally, this disturbance in the architecture of the eye – especially in the fovea – results in scarring, causing permanent loss of vision.
AMD is influenced by genetics as well as environmental factors, such as diet and smoking, which are the most consistent non-genetic risk factors. Furthermore, hypertension and hyperlipidemia have been associated with AMD as well, and contribute in up to 75% of AMD cases. Vascular endothelial growth factor-A (VEGF-A) plays a critical role in the pathogenesis of neovascular AMD through its effects on angiogenesis and vascular permeability. Elevated levels of VEGF-A have been found in CNV membranes from patients with AMD. Ranibizumab targets all VEGF-A isoforms. Thus, this neovascular AMD treatment demonstrates stabilization and even improvement in vision for many patients.

Polypoidal choroidal vasculopathy
Polypoidal choroidal vasculopathy (PCV) was first identified as a distinct form of wet AMD in 1990 by Yannuzzi et al who reported a series of patients with polypoidal, subretinal vascular lesions that cause serous and/or hemorrhagic detachment of the RPE and exudative macular degeneration. Thus, it was described to be an abnormality of the choroidal vasculature and now represents a separate type of CNV.

Several studies have suggested that genetic and environmental factors are associated with the clinical features of PCV, and systemic and ocular risk factors have been reported, such as systemic hypertension, elevated C-reactive protein (CRP) levels, smoking, central serous chorioretinopathy, RPE rips and tears, and pigment epithelial detachment (PED).

Photodynamic treatment (PDT) with verteporfin is one of the most widely described treatment modalities for PCV in the literature. The intravitreal (IVT) injection of anti-VEGF agents against PCV and its outcomes is still questionable because studies have reported that PCV lesions were not resolved by anti-VEGF monotherapy. On the other hand, there are recent studies that contradict these findings by pointing out the disappearance of the polypoidal lesions and regression of the branching vascular network after anti-VEGF monotherapy, mostly because of its improved penetration due to its small molecular size. Treatment with ranibizumab appears to significantly decrease bleeding and exudation in PCV.

Myopic degeneration
Although myopia is a common visual disorder in the world, pathologic myopia is characterized by progressive anteroposterior elongation of the sclera and is associated with several complications. Its prevalence is 25% in the US and Western Europe and higher (40%–70%) in Asians. Myopic eyes with very long axial lengths (≥26 mm) or a high degree of myopic refractive error (≥−6 diopters) are classified as high myopia.

In highly myopic eyes, choroidal atrophy and neovascularization are the most vision-threatening complications. Myopia is responsible for 62% of CNV cases in patients younger than 50 years with unfavorable prognosis. Visual acuity (VA) at 5 years after the onset of CNV decreases to ≤20/200 in 89% of eyes and in 96% of eyes after 10 years. It is difficult to prevent the development of myopia and CNV, so preserving VA represents the most important factor for myopic patients.

Anti-VEGF therapy has been used for the treatment of myopic CNV since 2005 and has shown good outcomes. VA improves in many cases and smaller CNV size contributes to good prognosis. CNV due to myopia has been shown to respond faster to ranibizumab treatment compared to CNV due to neovascular AMD and fewer injections are necessary to reach stabilization of VA.

Diabetic macular edema
Diabetes is a chronic condition characterized by elevated levels of glucose, and increases the risk of cardiovascular diseases, kidney failure, and nerve damage leading to serious complications. Ocular complications include Diabetic macular edema (DME), which is the main reason for deteriorated VA in industrialized countries. Nowadays, blindness from DME is preventable with detection and appropriate therapy. Treatment includes control of glycemia, arterial hypertension, and renal status.

DME is considered to be a result of breakdown of the vascular inner blood–retinal barrier (BRB), and occurs in one of two ways: 1) focal leakage from microaneurysms and 2) diffuse leakage from the walls of capillaries.

The exact mechanism by which diabetes leads to DME is not known, but it is indicated that high glucose levels over time correlate with the onset and progression of diabetic retinopathy. Research has identified that VEGF expression plays a key role in its development.

Laser treatment has been an established strategy of treatment for DME for several years, and reduces the vision loss. Treatment for clinically significant (diabetic) macular edema (ME) has been focal/grid laser photocoagulation based on the Early Treatment Diabetic Retinopathy Study (ETDRS). Laser is applied to leaking microaneurysms and a grid pattern of larger burns at the level of the RPE is used to treat leakage. The destruction of the RPE induces apoptosis.
of retinal cells. In the macular area, secondary effects, such as enlargement of atrophic spots, affect VA.

Ranibizumab is the only anti-VEGF drug that has been approved by the US Food and Drug Administration (FDA) for the treatment of DME. Ranibizumab therapy represents an effective therapeutic agent for the treatment of DME and appears to improve retinal function, while recent trials have demonstrated that IVT injections can significantly induce resolution of edema and improve the VA of patients with DME.

Retinal vein occlusion
Retinal vein occlusion (RVO) is the second most commonly occurring retinal vascular abnormality after diabetic retinopathy and is a significant cause of vision loss. The pathogenesis includes occlusion of veins by vascular clot, external compression, or damage to the vessel wall. Occlusion can occur either in the central retinal vein (central RVO [CRVO]) or branches of the retinal veins (branch RVO [BRVO]) and prognosis varies depending on which is occluded. VEGF plays an important role in the pathogenesis of ME in both CRVO and BRVO as they both lead to fluid leakage from capillaries, caused by the secretion of VEGF, and result in edema.

The clinical presentation of patients with BRVO is less severe than that seen in patients with CRVO, because venous return is compromised in approximately less than half of the retina, rather than the entire retina. The major cause of visual loss in patients with RVO is ME, and nonperfusion of perifoveal capillaries also contributes to this. To date, grid or focal laser photocoagulation have been shown to reduce the visual loss and even improve VA; however, there have been limitations to this treatment.

Recently, anti-inflammatory and anti-angiogenic therapeutic strategies have been used to target vascular permeability and leakage to reduce ME and improve vision. Corticosteroids (triamcinolone acetonide and dexamethasone) have shown potential to reduce edema in RVO. However, their side effects, such as cataract progression and elevation of intraocular pressure (IOP) have limited their use.

Consequently, treatment with anti-VEGF has been used successfully to treat ME and as elevated intraocular levels of VEGF have been demonstrated in patients with RVOs, anti-VEGF agents have been strongly suggested to be beneficial.

Retinitis pigmentosa
Retinitis pigmentosa (RP) is an inherited degenerative rod–cone retinal dystrophy caused by loss of photoreceptors, with a prevalence of 1/5,000. The basic symptom is night blindness, and in the long-run, patients suffer from progressive loss in the peripheral visual field. Finally, all these clinical symptoms result in blindness after several decades.

Clinical examination of RP patients reveals cell loss with consecutive retinal thinning, but there are cases where ME exists and is associated with RPE abnormalities, which derange the BRB, resulting in further reduction of VA in patients. In addition to RPE changes, it is possible that attenuation of choroidal blood flow may result in the development of PCV.

A prevalence of 11%–20% of cystoid ME (CME) in RP patients has been reported using fluorescein angiography (FA) and fundus exam.

Various treatments including topical and systemic carbonic anhydrase inhibitors, systemic corticosteroids, grid laser photocoagulation, and IVT triamcinolone acetonide (IVTA) have been used for the management of CME in RP patients, but have proven to be rather ineffective and include several complications.

In a study where IVT ranibizumab was used as monotherapy, although significant reduction in foveal thickness and resolution of edema was noted in RP patients, no improvement of VA was established.

Overview of pharmacology of ranibizumab
Angiogenesis consists of a series of biochemical and cellular processes that requires receptor activation by growth factors. Physiologic angiogenesis is necessary for human growth, maintenance, and repair; however when tissue hypoxia or inflammation occurs, pathologic angiogenesis enables tumor growth and causes tissue destruction. This is the reason why pathologic neovascularization and hyperpermeability in other organs, such as the eye, cause blindness from retinal detachment, uncontrollable glaucoma, and untreatable retinal edema.

The possibility that an inducible angiogenesis factor could be targeted to reduce tumor growth was first reported by Folkman in 1971. By 1983, vascular permeability factor was discovered, and after DNA sequencing and recognition of its role in angiogenesis, it was named VEGF. Therefore, various lines of investigation have identified VEGF as a critical molecule in angiogenesis.

Angiogenesis is the hallmark of neovascular AMD (wet AMD), the leading cause of blindness in the elderly population. It has been indicated that VEGF-A is a major mediator of angiogenesis and vascular leakage in wet AMD.
Several isoforms of VEGF-A can be generated due to alternative mRNA splicing.\textsuperscript{71}

Six forms of VEGF have been identified so far, produced by alternative splicing (VEGF\textsubscript{121}, VEGF\textsubscript{145}, VEGF\textsubscript{165}, VEGF\textsubscript{183}, VEGF\textsubscript{197} and VEGF\textsubscript{206}).\textsuperscript{71} The role that each form plays remains unclear, but retinal expression of VEGF\textsubscript{121} and VEGF\textsubscript{165} has been documented in normal eyes of rats, monkeys, and humans.\textsuperscript{72-75} VEGF is the key mediator in the development of choroidal neovascularization. Several VEGF inhibitors have been clinically developed. Among these, ranibizumab is a high-affinity recombinant antigen-binding fragment (Fab) that blocks all isoforms of VEGF-A.

Ranibizumab (Lucentis\textsuperscript{®,} Genentech, Inc., South San Francisco, CA, USA) is a humanized monoclonal antibody Fab engineered to bind with high affinity and to inhibit all biologically active isoforms of VEGF-A, so long as to block vessel permeability and angiogenesis.\textsuperscript{71} Ranibizumab was developed for intraocular administration as part of an anti-VEGF program in AMD.\textsuperscript{76} It has also been shown to penetrate all layers of the rabbit retina.\textsuperscript{77} Its small molecule size (48 kDa) seems to be the cause of this ability, because a full-length antibody (trastuzumab, 148 kDa) was not able to penetrate all the retinal layers in monkeys.\textsuperscript{77} Microautoradiography analysis indicated that ranibizumab penetrated all retinal layers, reaching the choriocapillaris.\textsuperscript{77}

Fabs have a shorter half-life than full-length antibodies and do not possess the fragment crystallizable (Fc) domain, which has the ability to induce immune system activation; thus, a Fab would prevent Fc-dependent activation and narrow systemic antibody exposure.\textsuperscript{71} Ranibizumab was specifically designed not to promote inflammation because it lacks the Fc region.

IVT administration of ranibizumab on a monthly or per needed basis contributes to the preservation and improvement of VA; resolution of ME, as measured by retinal thickness; and low rates of serious ocular or systemic adverse events (AEs).\textsuperscript{55,56,78-81} IVT injection was selected to maximize the VEGF inhibitory effect in the retina, while limiting systemic VEGF inhibition. Thus, it minimizes interference with the normal extraocular roles of VEGF.\textsuperscript{77}

The US FDA has approved ranibizumab for the treatment of neovascular (wet) AMD (initial approval: 2006), ME following RVO, and recently for treating DME.\textsuperscript{82-84}

In monkeys and rabbits, the concentration of ranibizumab in the ocular compartment (vitreous, retina, and aqueous humor) decays by 50% approximately every 3 days.\textsuperscript{85-87} Radioactivity from labeled ranibizumab molecules has been detected in all retinal layers, at 24-hour post-ITV injection. The distribution of ranibizumab into the retina and the aqueous humor following the injection implies that it reaches the systemic circulation by either entering the choroid vessels or via the aqueous humor outflow.\textsuperscript{85-87}

Following IVT administration, ranibizumab predominantly localizes to the injected eye, with very little reaching the fellow eye or systemic circulation. According to the manufacturer, serum ranibizumab concentrations are approximately 90,000-fold lower than vitreal concentrations, and well below that which is required to systemically inhibit 50% of the biological activity of VEGF, with a predicted serum concentration of 0.22 ng/mL when administered monthly.\textsuperscript{85} Systemic exposure has been measured in less than 0.01% of vitreous exposure.\textsuperscript{85} In monkeys, the serum elimination half-life (t\textsubscript{1/2}) of ranibizumab (0.5 mg) after IVT administration was 3.59 days, while it has a terminal half-life of 2.9 days in the ocular compartments.\textsuperscript{85} Extensive study of ranibizumab pharmacokinetics in the human eye is lacking and the pharmacokinetic information provided by the manufacturer is based on predictions from animal models and studies of human serum following IVT administration.\textsuperscript{88,89}

**Long-term efficacy**

Anti-VEGF drugs have become of utmost importance in the treatment of macular degenerative diseases. Consistent data regarding long-term efficacy (at least 2 years) are available for the treatment of the wet form of AMD with ranibizumab. The recent introduction of aflibercept in the treatment of wet AMD promises results with fewer injections.\textsuperscript{90}

Current research is focusing more on administration protocols to get the best long-term visual outcome and also potential new indications and on how to manage tachyphylaxis.\textsuperscript{91}

**Wet AMD**

Pegaptanib, assessed in the VISION study (590 patients, multicenter, randomized, placebo-controlled trial), was the first drug showing long-term efficacy in the treatment of wet AMD with a loss higher than 15 letters of VA at 54 weeks varying from 45% in the treated group versus 59% in the control group.\textsuperscript{6}

Ranibizumab was a revolution in long-term prognosis. It was the first drug that permitted a vision gain of 15 letters after 2 years in 26% and 33% of eyes treated respectively with 0.3 and 0.5 mg versus 4% in the control group (MARINA study; 716 patients, randomized, placebo-controlled, double-blind trial).\textsuperscript{80}
Finally, the long-term superiority of ranibizumab over verteporfin was proved in the same month with the ANCHOR study (423 patients, randomized, double-blind trial). At 1-year follow-up, vision gain of 15 letters was found in 36% and 40% of eyes treated respectively with 0.3 and 0.5 mg versus 6% in the verteporfin group. Long-term efficacy improved from less vision loss to stabilization, and finally to vision gain thanks to the development of anti-VEGF drugs. Nowadays, research is focused on efficiency by adapting administration protocol. First of all, treatment should not be delayed, as latency between diagnosis and effective treatment is associated with poorer outcome at 12 months. Therefore, treatment should be carried out without delay.

Reducing the amount of injection without inducing visual loss is the actual challenge. The loading dose during the first 3 months is the actual gold standard; Menghini et al could not show a benefit in VA at 2 years for patients having or not having received the loading dose; nevertheless, patients in both groups had the same amount of injections after 2 years’ follow-up. Quarterly injections after a 3-month loading seemed to be less effective at 2 years than monthly dosing (PIER study, randomized, double-blind with crossover trial) when compared to the MARINA or ANCHOR studies. The EXCITE study confirmed previous results, but with only a 1-year follow-up.

The HORIZON study included patients from the MARINA, ANCHOR, and FOCUS studies, treatment was administered at the investigator’s discretion, and follow-up was until 60 months. Roughly, initial VA gain returned to baseline in the initial treated group whereas visual acuity decline was lowered in the group treated with a 24-month delay, a difference of −16.1 letters (EDTRS) compared to the initially treated group was observed. Interestingly, 74% of patients from the treated group had VA loss after switching from a monthly injection to an investigator discretion administration protocol. This might be due to lack of injection (mean number of injections after the initial 2 years of monthly injections: 4.4±5.3 [standard deviation]), but could also be due to the progression of the AMD disease itself.

Injection protocol based only on VA impairment (ie, loss of five letters on the ETDRS) was associated with a poor outcome at 24 months (best corrected VA [BCVA] decline by 4.3 letters from baseline) in the SECURE study. Therefore, actual treatment is based on a pro re nata (as needed) approach (VA, clinical examination, and imaging criteria) or treat and extend approach with a gradually extending interval of injections depending on fluid recurrence rate. Long-term data on alternative regimen administration protocol are encouraging with an improvement in VA and decrease to five injections per year based on in between protocol (pro re nata and extend) or only a small decline of VA after 2 years when compared with monthly injections.

Recent literature also focuses on more cost-effective alternatives to ranibizumab. Bevacizumab and ranibizumab seem to have equivalent visual outcome at 1 (CATT trial) and 2 years but with a huge cost difference. Also, the sequential use of a loading dose of ranibizumab (nonselective VEGF inhibitors) followed by pegaptanib (selective VEGF inhibitor) as maintenance therapy shows good results at 1 year but needs further long-term assessment. This could be an alternative in patients with systemic comorbidities.

VA at 2 years after treatment of PCV, a variant of wet AMD, was associated with a better outcome for patients in the ranibizumab group versus PDT group in a Japanese population.

Long-term equivalence of aflibercept and ranibizumab was confirmed in the VIEW study (randomized, double-blinded, controlled study). Administration protocol was 2 mg aflibercept every 8 weeks after three monthly injections or 0.5 mg ranibizumab every 4 weeks during the first year and then as needed. Results in BCVA at 96 weeks were similar but with five fewer injections in the aflibercept group.

CME in diabetic patients
The RESOLVE trial (12-month, multicenter, sham-controlled, double-masked study) reported improved VA (by 10.3±9.1 letters) in DME patients treated with ranibizumab, while reduction by 1.4±14.2 letters was found in the sham group (P<0.0001). Similarly, the mean central retinal thickness (CRT) reduction was 194.2±135.1 μm with ranibizumab versus 48.4±153.4 μm with sham (P<0.0001). The RISE and RIDE trials demonstrated that a greater proportion of ranibizumab-treated patients had more than 15 letters gain in vision compared with placebo groups.

The 3-year outcome from the READ-2 study (prospective, multicenter, randomized study) was in favor of prolonged ranibizumab treatment for DME. VA improved from 7.2 at 24 months to 10.3 ETDRS letters at 36 months. An important prognostic factor is baseline VA with a poor visual outcome at 2 years if the initial VA was at or lower than 20/125.

RVO
In the RETAIN study (prospective follow-up of RVO trials’ patients) 44% of patients with CRVO (treated with ranibizumab) had resolution of CME
and a visual recovery of more than 20/40 in 64% of patients versus 28% in the unresolved group.\textsuperscript{109} Seventy percent of patients in the resolved CME group received their last injection within the first 2 years of treatment, whereas in the unresolved group, patients still needed frequent injections after 4 years. Therefore, unresolved CME in CRVO within the first 2 years is considered to be a bad prognostic factor. Seventy-six percent of BRVO patients had resolution of CME within 2 years, with a mean ETDRS VA of 74 letters at 48 months. Only 3.2 injections were necessary at year 4 in the unresolved group.

The GALILEO study (randomized, double-blind, multicenter study) assessed aflibercept efficacy to improve VA in CME secondary to CRVO in comparison to sham injection.\textsuperscript{110} VA improved in 60% of the aflibercept group versus 30.4% in the sham group at 52 weeks. There are no long-term data available to date.

**Myopia**

Bevacizumab achieved complete closure in more than 90% of CNV in myopic patients at 2 years.\textsuperscript{111} Both bevacizumab and ranibizumab were effective in maintaining VA at 2 years, with only a slight decline when compared with 1-year results in myopic subfoveal CNV. The gain was 2.8 and 5.1 lines, respectively, in the bevacizumab and ranibizumab groups, with mean VA improvements from 20/145 to 20/60. No statistical difference was found between the two groups.\textsuperscript{112}

A slight decline in VA after 2 years’ follow-up was also confirmed by Yang et al probably due to the progression of macular myopic degeneration. Prognostic factors for a poor visual outcome were: baseline VA, recurrence, CNV size, and thickness of the choroid.\textsuperscript{113}

Anti-VEGF treatment with ranibizumab also has promising results in complicated neovascular AMD with PED,\textsuperscript{114,115} CNV secondary to causes other than AMD,\textsuperscript{116} other inflammatory diseases,\textsuperscript{117,118} and retinopathy of prematurity.\textsuperscript{119} Efforts should be made to obtain more long-term data in these areas.

A summary of the most important clinical trials is depicted in Table 1.

**Safety and tolerability**

VEGF inhibitors, such as ranibizumab, play an important role in the management of retinal degenerative diseases. Their efficacy is unquestionable; however, the safety of IVT administration of ranibizumab is controversial as some evidence suggests that it may increase the risk of systemic side effects.\textsuperscript{120–123}

**AMD**

Both the ANCHOR and MARINA studies showed that ranibizumab is safe and well-tolerated.\textsuperscript{79,80} There were no significant differences in ocular and non-ocular AEs between the ranibizumab groups and PDT or placebo controls. Ocular AEs included endophthalmitis, uveitis, vitreous hemorrhage, retinal detachment, retinal tear, or lens damage. Non-ocular (systemic) AEs included thromboembolic events (stroke, myocardial infarction), hypertension, and non-ocular hemorrhage.

The PIER study reported no ocular AEs such as endophthalmitis, uveitis, vitreous hemorrhage, rhegmatogenous retinal detachment, retinal tear, or lens damage.\textsuperscript{93,124} The rate of thromboembolic events was 0% in the ranibizumab group in the first year of the study,\textsuperscript{124} and 1.7% only for the 0.3 mg group in the second year.\textsuperscript{93}

The SUSTAIN study reported ocular AEs, including retinal hemorrhage, cataract, and RPE tear only in 1.2% of patients, while vitreous hemorrhage and thromboembolic events were observed in 3.7% of the patients.\textsuperscript{125}

The SAILOR study reported ocular AEs including endophthalmitis and pseudoendophthalmitis in <1% of patients.\textsuperscript{126} The study showed a slightly higher risk of stroke in the 0.5 mg versus 0.3 mg group (1.2% versus 0.6%, difference not significant). A previous history of stroke, arrhythmia, and congestive heart failure were found to be risk factors for stroke in the study.

Recently, the SECURE study showed that ranibizumab administered at the investigator’s discretion as per the European Summary of Product Characteristics 2007 (SmPC, VA-guided flexible dosing regimen) was safe and well-tolerated over 2 years.\textsuperscript{97} The most frequent ocular AEs were retinal hemorrhage (12.8%), cataract (11.5%), and increased IOP (6.4%). The study also reported systemic AEs, such as hypertension (9%), nasopharyngitis (9%), and thromboembolic events (5.6%). None of the deaths (2.1%) that occurred during the study were related to the drug.

**CME in diabetic patients**

In the RESOLVE study (12-month, multicenter, sham-controlled, double-masked study), ranibizumab was found to be safe with ocular and systemic AEs being comparable between the treatment and control groups.\textsuperscript{41} Similarly, the READ-2 study reported no retinal toxic effects for up to 3 years.\textsuperscript{107} In the RISE and RIDE trials (randomized, multicenter, double-masked, 3-year trials, sham injection-controlled for 2 years), ranibizumab treatment was found to be safe, with a low incidence of serious AEs (19.7% in the
0.5 mg group and 19.8% in the 0.3 mg group), and without significant increase in the incidence of deaths. Recently, the RESTORE extension study (Phase IIIb, multicenter, 12-month, randomized core study and 24-month open-label extension study) reported no cases of endophthalmitis, retinal tear, or retinal detachment. The most frequent ocular and non-ocular AEs over 3 years were cataract (16.3%) and nasopharyngitis (23.3%), respectively. There were no deaths related to the drug.

**RVO**

The BRAVO and CRUISE trials reported increased IOP (5.4% and 8.5%, respectively) in patients receiving 0.5 mg ranibizumab; low incidence of cataract (<4% in both studies); no retinal detachment; and only one case of endophthalmitis (in the BRAVO study, 0.5 mg ranibizumab group). Recently, the RETAIN study reported four severe ocular AEs (retinal tear, vitreous hemorrhage, severe reaction to povidone-iodine, and superior hemi-RVO) that were

### Table 1 Summary of the most important clinical ranibizumab trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Number of patients</th>
<th>Key results</th>
</tr>
</thead>
</table>
| Wet AMD   | Anchor<sup>16,17</sup> Multicenter, randomized, double-masked, active-treatment-controlled clinical trial, 2-year | 423                | 1) 94.3% of patients given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost <15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison)
          |                                                  |                    | 2) VA improved by ≥15 letters in 35.7% of the 0.3 mg group and 40.3% of the 0.5 mg group, compared with 5.6% of the verteporfin group (P<0.001 for each comparison) |
| MARINA    | Multicenter, 2-year, double-blind, sham-controlled study | 716                | VA improved by ≥15 letters in 24.8% of the 0.3 mg group and 33.8% of the 0.5 mg group, as compared with 5.0% of the sham-injection group (P<0.001 for both doses) |
| PIER<sup>17,18</sup> | Phase IIIb, multicenter, randomized, double-masked, 2-year, sham injection-controlled trial | 184                | VA decreased an average of 21.4, 2.2, and 2.3 letters from baseline in the sham, 0.3 mg, and 0.5 mg groups (P<0.0001 for each ranibizumab group vs sham) |
| PrONTO    | 2-year prospective, uncontrolled, variable-dosing regimen based on OCT | 40 (37 completed the study) | Mean VA improved by 11.1 letters (P<0.001) and the OCT-CRT decreased by 212 μm (P<0.001). These outcomes were achieved with an average of 9.9 injections over 24 months |
| RVO       | BRAVO<sup>28</sup> Multicenter, double-masked, 6-month trial | 397                | Patients treated with ranibizumab reported greater mean improvements in visual function, with substantial differences observed as early as month 1 compared with sham patients (all P<0.05) |
|          | CRUISE<sup>28</sup> Multicenter, double-masked, 6-month trial | 392                | Patients treated with ranibizumab reported greater mean improvements in visual function, with substantial differences observed as early as month 1 compared with sham patients (all P<0.05) |
|          | RETAIN<sup>19</sup> Prospective follow-up of a subset of patients from two Phase III trials (Genentech-sponsored ranibizumab study RVO trials). Mean follow-up of 49.0 months for BRVO patients and 49.7 months for CRVO | 66                 | 1) 50% of BRVO patients had edema resolution; 80% of BRVO patients had a final VA ≥20/40
          |                                                  |                    | 2) 44% of CRVO patients had edema resolution; 64.3% of patients with resolved ME vs 27.8% of patients with unresolved ME had a final VA ≥20/40 |
| DME       | RESOLVE<sup>21</sup> 12-month, multicenter, sham-controlled, double-masked study | 151                | 1) VA improved from baseline by 10.3±1.1 letters with ranibizumab and declined by 1.4±1.2 letters with sham (P<0.0001)
          |                                                  |                    | 2) Mean CRT reduction was 194±131.1 μm with ranibizumab and 48±153.4 μm with sham (P<0.0001) |
|          | RISE<sup>24</sup> Phase III, randomized, multicenter, double-masked, 3-year trials, sham injection-controlled for 2 years | 377                | Greater proportion of ranibizumab-treated patients had ≥15 letters gain in vision compared with placebo group, with 51.2% for the 0.3 mg ranibizumab group, 41.6% for the 0.5 mg ranibizumab group, vs 22.0% for the placebo groups (P<0.0001) |
|          | RIDE<sup>25</sup> Phase III, randomized, multicenter, double-masked, 3-year trials, sham injection-controlled for 2 years | 382                | Greater proportion of ranibizumab-treated patients had ≥15 letters gain in vision compared with placebo group, with 36.8% for the 0.3 mg ranibizumab group, 40.2% for the 0.5 mg ranibizumab group, vs 19.2% for the placebo groups (P<0.0001) |

**Abbreviations:** AMD, age-related macular degeneration; BRVO, branch retinal vein occlusion; CRT, central retinal thickness; CRVO, central retinal vein occlusion; DME, diabetic macular edema; ME, macular edema; OCT, optical coherence tomography; RVO, retinal vein occlusion; VA, visual acuity; vs, versus.
not related to ranibizumab. Thirteen patients experienced severe systemic AEs, such as tachycardia, chest discomfort, syncope, and arrhythmia; none of these were attributable to the drug.

For the time being, there are no long-term data on the safety of ranibizumab treatment for myopic CNV, inflammatory CNV, and retinopathy of prematurity (ROP). A recent study by Castellanos et al (six patients, 3 years’ follow-up), reported complete resolution of neovascularization in patients with ROP after a single injection, with no AEs. Further larger and longer studies are needed to address the long-term safety and efficacy for these conditions.

**Patient-reported outcomes – quality of life**

In a recent study by Finger et al (multicenter, noninterventional study with 3,470 wet AMD patients, upload period: 3 months, final follow-up: 12 months), an improvement of subjective vision was reported by 46.3% of patients at first follow-up after upload and by 29.5% at the final follow-up. Patients’ voice-related quality of life (National Eye Institute 25-item Visual Function Questionnaire [NEI-VFQ 25] summary score) showed positive stabilization with a mean change of 0.73 (standard error = 0.37, P = 0.0501) compared with baseline.

Frennesson et al observed improved quality of life for distance activities from 54±28 points to 63±28 points (P < 0.0001), but significantly (P = 0.024) more for near activities, from 49±26 points to 63±26 points (P < 0.0001).

Reading newspaper text showed the highest increase of all in the quality of life score.

On the other hand, a prospective single-center study by Rung and Lövestam-Adrian (50 patients with wet AMD treated with ranibizumab, with a loading dose of three monthly injections and decision on reinjection according to VA and optical coherence tomography findings, 3 years’ follow-up), using the NEI-VFQ 25, reported no significant decrease in mental health (P = 0.529) or ability to read a newspaper (P = 0.21), but did report decreases in distance activities (reading street signs, steps, going to the theater) from 57±27 points to 46±31 points (P = 0.007).

Finally, the HELIOS study (prospective, observational, multicenter, open-label study of 0.5 mg of ranibizumab, follow-up of 24±3 months) showed that at 6 months, improvements over baseline were significant for both NEI-VFQ 25 (P = 0.03) and the Health Utilities Index Mark 3 (HUI3; P = 0.02), but not at 12 and 24 months, and that improvement was maintained at 24 months in 38% (NEI-VFQ 25) and 34% (HUI3) of patients.

**Conclusion**

Ranibizumab is an efficient and safe treatment for various degenerative ocular conditions, such as AMD, DME, and ME secondary to RVO. The LUMINOUS program (5-year prospective, multicenter, noninterventional study, with planned sample size of 30,000 subjects worldwide) is currently evaluating the long-term safety and efficacy of ranibizumab in addition to understanding its treatment patterns and outcomes for wet AMD and DME in the real-world clinical setting.

Ranibizumab also seems to be efficient and safe for the treatment of other degenerative ocular conditions, such as myopic and inflammatory CNV and ROP. Recently, ranibizumab was found to be effective in the treatment of corneal neovascularization as well. Research should be focused on these topics.

Finally another anti-VEGF drug, VEGF-trap aflibercept (Eylea®, Regeneron, Tarrytown, NY, USA; Bayer AG, Leverkusen, Germany) has been recently approved for the treatment of wet AMD. The VIEW-1 and VIEW-2 trials showed that aflibercept is an effective treatment for wet AMD, promising to decrease the frequency of injections and subsequently reduce the risk from monthly IVT injections. Similarly, the GALILEO study showed significant functional and anatomic benefits after 1 year in patients with ME secondary to CRVO treated with aflibercept. However, ranibizumab still remains the gold standard treatment for the majority of degenerative ocular conditions. Future research results are anticipated with great interest.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


